Main container

Palmerini Emanuela, MD


Date of Birth


Title of qualification awarded

2000: Degree in Medicine and Surgery, University of Bologna, final grade: 110/110, with honors.

Other qualifications awarded

2004: Medical Oncology Fellowship, Bologna, with grade 70/70, with honors.
2006: Master in Breast Cancer, University of Turin and Bologna.
From 2014: Oncology, Haematology, Pathology PhD.

Positions held
  • 2004-2005: AIRC Research Grant, Ospedale Bellaria Bologna;
  • 2005- 2010: Attending Staff Physician, Research Contract, Department of Chemotherapy for rare musculoskeletal tumors, Rizzoli Orthopaedic Institute;
  • From 2010: Prometeo Laboratory, Clinical and Experimental Research Contract, Department of Chemotherapy for rare musculoskeletal tumors, Rizzoli Orthopaedic Institute.

Mother language: Italian.
Other languages: English (excellent), French (fluent).


Office (Word, Excel, PowerPoint), SPSS.

Teaching activities

Elective Course of Medical tratment of Bone Metastases, Faculty of Medicine.

Scientific activities

Research Grants:

  • 2004-2005: AIRC Research  Grant, Ospedale Bellaria Bologna (FIRC: Italian Foundation for Cancer Research): Mechanisms of endocrine therapy resistance: estrogen receptor and epidermal growth factor receptor in breast cancer;
  • 2013: 3-year Young Investigators Translational  Research Grant “Alessandro Liberati”: Assessment of MGMT promoter methylation and clinical benefit from temozolomide-based therapy in Ewing sarcoma patients.

Clinical Research Experience:

  • 2001: Visiting Research Fellow,  Rockefeller University, New Yor;
  • 2001: Clinical Observer, Memorial Sloan-Kettering Cancer Center, New York;
  • 2003: Dompè Course, “Anemia in cancer patients” Karolinska Institute, Stockholm;
  • 2006: ESMO Translational Research Unit Visit, Institute Gustave Roussy, Paris;
  • 2007: 1° ESH/EBMT Course: “Blood and marrow  transplantation Children”, Genova

Scientific and Medical Societies:

  • 2003-present: American Society of Clinical Oncology (ASCO);
  • 2004-present:  Italian Society of Medical Oncology (AIOM);
  • 2005-present: European Society for Medical oncology (ESMO).


  • 2002:  “Evaristo Stefanelli” Award,  Università di Bologna;
  • 2003: “Lancet Travel Grant”, to attend the 39° ASCO Annual Meeting;
  • 2004: FIRC-AIRC Grant;
  • 2005, 2006, 2008, 2009: ASCO Foundation Abstract Merit Award”;
  • 2005: Special correspondent Project, AMGEN, to attend the 41° ASCO Annual Meeting;
  • 2006: “ESMO Translational Research Unit Visit Award”, Istituto Gustave Roussy;
  • 2006: AIOM Best Abstract Award";
  • 2010: ESMO Congress Travel Grant;
  • 2014: ESMO Congress Travel Grant, Madrid, Spain.

Pubblications. Author of several papers (>45) on international scientific journals and author of 3 book chapters.


Clinical Protocol Experience (Phase II, role: sub-I):

  • Pemetrexed (Alimta, ®Lilly) in metastatic osteosarcoma
  • STI571 (Glivec, ®Novartis) in chondrosarcoma
  • ET 743 (Yondelis, Pharmamar) neoadjuvant in sarcomas
  • ET 743 (Yondelis, Pharmamar) metastatic sarcomas
  • CP-751,871 (Pfizer) in metastatic Ewing sarcomas
  • Denosumab (Amgen) in metastatic/unresectable GCT
  • Lapatinib (Tyverb®) in advanced chordomas
  • R1507 (Roche) in metastatic Ewing  sarcomas
  • Deforolimus (Ariad), in responding sarcomas
  • IPI 926 (Infinity), in metastastic chondrosarcomas
  • Zalypsis® (PM00104), in metastastic  Ewing sarcoma
  • Sorafenib/Everolimus in metastatic osteosarcoma
  • NGR-hTNF in metastastatic soft tissue sarcoma
  • ISG STS 10.01: targeted vs. untargeted STS adjuvant
  • Morab-004 (Morphotek) in metastatic sarcoma
Clinical and/or Scientific interests

Musculoskeletal Oncology, Bone and Soft Tissue tumors Clinical Research Protocols.

Clinical Studies

Studi clinici promossi dal professionista.

Clinical Trial
A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Read more
Clinical Trial
Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors
Read more